A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia Secondary to SIADH in Italy
Latest Information Update: 04 Mar 2021
Price :
$35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Therapeutic Use
- Acronyms ASSERT
- Sponsors Otsuka Pharmaceutical Europe
- 31 Jan 2021 Results of lung cancer cohort presented at the 2020 World Conference on Lung Cancer
- 14 Feb 2020 New trial record